Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Comment by lscfaon Jun 09, 2021 12:02pm
189 Views
Post# 33355309

RE:Value is $0.20

RE:Value is $0.20

 

$cdn

2020 9 mo

2019

 

Revenue

9,814,534

15,882,545

 

Gross profit

2,419,254

3,075,786

 

ebitda

831,358

1,094,389

 

Net income (loss)

(180,289)

(1,428,807)

 

 

 

 

 

Gross margin 

24.6%

19.4%

 

ebitda margin

8.5%

6.9%

 

 

 

 

 

 

 

 

 

$US

2020 9 mo

2019

2018

Revenue

7,248,013

11,969,662

9,309,154

Gross profit

1,786,615

2,318,024

2,841,968

ebitda

613,956

824,771

526,515

Net income (loss)

(133,143)

(1,351,907)

(788,125)

 

 

 

 

Gross margin 

24.6%

19.4%

30.5%

ebitda margin

8.5%

6.9%

5.7%

 

<< Previous
Bullboard Posts
Next >>